Beta-blockers in heart failure patients with severe chronic kidney disease-time for a randomized controlled trial?

the Modification of Diet in Renal suggested a small of dietary protein restriction on the progression of chronic kidney disease one to of protein on CKD

[1]  A. Garg,et al.  The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  A. DeVore,et al.  Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. , 2019, JACC. Heart failure.

[3]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[4]  Jonathan H Seltzer,et al.  Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints , 2019, European heart journal.

[5]  Adrian F Hernandez,et al.  Heart failure drug treatment , 2019, The Lancet.

[6]  R. Agarwal,et al.  Big data in nephrology—a time to rethink , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  F. Zannad,et al.  Cardiovascular Outcome Trials in Patients With Advanced Kidney Disease: Time for Action. , 2017, Circulation.

[8]  G. Fonarow,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Circulation.

[9]  B. Pitt,et al.  Roadmap for cardiovascular prevention trials in chronic kidney disease , 2016, The Lancet.

[10]  P. Kirchhof,et al.  Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis , 2014, The Lancet.

[11]  Getachew Tegegne,et al.  Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  L. Køber,et al.  Incidence and Predictors of End-Stage Renal Disease in Outpatients With Systolic Heart Failure , 2013, Circulation. Heart failure.

[13]  Andreas Stang,et al.  Common problems related to the use of number needed to treat. , 2010, Journal of clinical epidemiology.

[14]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.